跳至主要内容
临床试验/NCT00106821
NCT00106821已完成4 期

An 8 Week Randomized, Placebo Controlled, Double-blind Study to Assess the Efficacy of Tiotropium Inhalation Capsules in Patients of African Descent With Chronic Obstructive Pulmonary Disease

Boehringer Ingelheim22 个研究点 分布在 1 个国家目标入组 166 人开始时间: 2004年6月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
166
试验地点
22
主要终点
The primary efficacy endpoint will be FEV1 AUC (0-3) after 8 weeks of treatment

研究概览

简要总结

The purpose of this study is to look at the benefits of tiotropium, an approved drug for the treatment of bronchospasm associated with COPD (chronic obstructive pulmonary disease), in a population of patients with COPD who are of African American descent.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female of African descent
  • 40 years of age or older
  • Diagnosis of COPD
  • History of smoking at least one pack per day for at least 10 years
  • Currently experiencing shortness of breath at least with exertion

排除标准

  • Recent myocardial infarction or hospitalization for congestive heart failure

结局指标

主要结局

The primary efficacy endpoint will be FEV1 AUC (0-3) after 8 weeks of treatment

次要结局

  • FEV1 AUC0-3 after single dose, 4 weeks of treatment, peak FEV1 on each test day, trough FEV1 at weeks 4 & 8, FVC trough (weeks 4 & 8), peak and AUC(0-3) (on all test days), FEV1 and FVC at all time points, rescue albuterol use, dyspnea SOP questionnaire

研究者

申办方类型
Industry

研究点 (22)

Loading locations...

相似试验